Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
Tomography (Ann Arbor, Mich.)|February 24, 2022
Integrating the OHIF Viewer into XNAT: Achievements, Challenges and Prospects for Quantitative Imaging StudiesSimon J Doran, Mohammad Al Sa'd, James A Petts, et al.Annals of Neurology|April 25, 2018
Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial resultsLee H Schwamm, Ona Wu, Shlee S Song, et al.Neurology|August 17, 2016
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosisShivani Ahlawat, Laura M Fayad, Muhammad Shayan Khan, et al.Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerNancy U Lin, Lisa A Carey, Minetta C Liu, et al.Breast Cancer Research and Treatment|November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastasesNancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.Neurology|August 29, 2019
Early molecular oxidative stress biomarkers of ischemic penumbra in acute strokeSvetlana Lorenzano, Natalia S Rost, Muhib Khan, et al.Stroke|January 27, 2018
Oxidative Stress Biomarkers of Brain Damage: Hyperacute Plasma F2-Isoprostane Predicts Infarct Growth in StrokeSvetlana Lorenzano, Natalia S Rost, Muhib Khan, et al.The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.Pageof 8